XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Note 20 - Segment Reporting
 12 Months Ended
Dec. 31, 2023
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

NOTE 20. SEGMENT REPORTING

 

The Company’s CODM, who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

 

The Company is managed in two segments and aggregates its operational and financial information accordingly: (1) Eyecare & Wound Care and (2) Skincare. The Eyecare & Wound Care segment consists primarily of eyecare products sold under the Avenova brand name as well as wound care products sold under the NeutroPhase and PhaseOne brands. The Skincare segment consists of products sold under the DERMAdoctor brand. Subsequent to December 31, 2023, on March 25, 2024, we closed the DERMAdoctor Divestiture, resulting in the sale of all of our Skincare segment. See additional information in Note 21, “Subsequent Events”.

 

Select financial information for each segment is as follows (in thousands):

 

  

Year

      

Year

     
  

Ended

      

Ended

     
  

December 31,

  

Percentage

  

December 31,

  

Percentage

 
  

2023

  

of Total

  

2022

  

of Total

 

Eyecare & Wound Care

 $11,174   76% $10,239   71%

Skincare

  3,552   24%  4,165   29%

Total sales, net

 $14,726   100% $14,404   100%
                 

Eyecare & Wound Care

 $3,650   48% $5,645   39%

Skincare

  3,946   52%  8,772   61%

Total operating loss

 $7,596   100% $14,417   100%